Our Mission

Mission Statement

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit.

Public Benefit

What is the Benefit of a Public Benefit Corporation?

 

Shared Guiding Principles

Patients First. Learn About Our Purpose and Mission.

Who We Are

We Strive for Public Benefit. We Are the Members of MAPS PBC. 

What is a Public Benefit Corporation?

A Public Benefit Corporation is a new type of corporation that is driven by values that promote sustainability, accountability, and transparency.

  • Sustainability: We use profits to continue research to benefit society.
  • Accountability: We take our impact on society and the environment into consideration.
  • Transparency: We are required to report and share progress towards our impact on society.

Our Relationship to MAPS

MAPS Public Benefit Corporation (MAPS PBC), is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS).

The Mission of MAPS

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Shared Guiding Principles

  • Patients first and profits for care – Accessible mental health treatments for those who are in need.
  • Transparency — Commitment to open-science principles.
  • Passion and Perseverance — We persist in the face of challenges.
  • Intelligent Risk — Our decisions are informed by research.
  • Trust and Accountability — We value integrity and honesty, and embrace high standards.

*MAPS Public Benefit Corporation is owned by one shareholder.

MAPS PBC is Committed to Collective Liberation

MAPS PBC is committed to collective liberation. We acknowledge the existence of historic and systemic oppression and recognizes that a truly liberated future can only exist if all people, including and especially those who have been impacted by these injustices, are included in its creation. Collective liberation recognizes that all of our struggles are intimately connected, and that within systems of oppression, everyone suffers.

Who We Are

MAPS Public Benefit Corporation

Established in 2014

Come work with us!

Board of Directors

Dan Grossman

Dan Grossman

Dan Grossman is a Managing Director & Senior Partner at Boston Consulting Group (BCG), one of the world’s preeminent management consulting firms. He has close to 20 years of experience in BCG’s Health Care Practice Area, working with leading biopharmaceutical and medical technology companies on issues of corporate strategy, pipeline development, and commercializing innovation globally. His experience spans therapeutic areas, with significant depth across major areas of neuroscience. He has served as the head of Learning & Development for BCG in North America, and is responsible for BCG’s portfolio of proprietary data and software tools for the Health Care Practice. Grossman also serves as Treasurer and Executive Committee member of the Board of Trustees of the Lyric Opera of Chicago. He holds a Ph.D. from Princeton University and a B.A. from Harvard College.

Jeff George

Jeff George

 Jeff is the Managing Partner of Maytal Capital, a healthcare-focused private equity and venture capital firm he founded in 2017, a Partner at Bridge Builders Collaborative, an early-stage venture firm focused on mental health, and an Operating Partner at Revival Healthcare Capital, a medical device-focused private equity firm. He previously served as the global CEO for Sandoz and Alcon at Novartis Group (NYSE: NVS), where he served on the Executive Committee. 

Jeff currently serves on the board of directors of Amneal Pharmaceuticals (NYSE: AMRX), a leader in specialty and generic pharmaceuticals with over $2 billion in revenues; Dorian Therapeutics, a cell therapy biotech spun out of Stanford University; 908 Devices (NASDAQ: MASS), a high-growth pioneer in life science diagnostics; and Wishbone Medical, a leader in pediatric orthopedic medical devices. He also serves on several non-profit boards including Education Opens Doors, where he serves as Board Chair, the North Texas Food Bank, and YPO of Dallas. 

Between 2008 and 2016, Jeff served on the Executive Committee of Switzerland-based Novartis Group, first as the global CEO of Germany-based Sandoz, Novartis’s $10 billion revenue generic pharma and biosimilar subsidiary, and then as CEO of Texas-based Alcon, Novartis’s $10 billion revenue eye care division, which was spun out from Novartis as a publicly-listed firm (NYSE: ALC) in 2019. At both Sandoz and Alcon, Jeff was responsible for leading over 25,000 associates across more than 160 countries and had leadership responsibility for all functions, regions, and franchises. 

Prior to these roles, Jeff headed Emerging Markets for the Middle East, Africa, Southeast Asia, and CIS at Novartis Pharmaceuticals, leading a team of over 3,000 people across 65 markets and serving on its Executive Committee, and as Vice President and Head of Western & Eastern Europe for Novartis Vaccines. Before joining Novartis, Jeff was a Senior Director of Strategic Planning & Business Development at Gap Inc. and an Engagement Manager with McKinsey & Co., both in San Francisco. 

Jeff holds an MBA from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was a John W. Watzek Fellow. He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College. Jeff currently serves as a Board Trustee at Breck School, his high school alma mater in Minneapolis. 

Jeff previously served on the Board of Directors of AdvaMed, the medical device industry association, between 2014 and 2016, and between 2017 and 2020 at Roam Analytics, a Silicon Valley-based artificial intelligence healthcare software firm sold to Parexel in 2020. He was twice named to Fortune’s “40 under 40” global leaders list and has lived in seven countries on four continents. He is married and lives with his wife and two daughters in Dallas and enjoys running, skiing, live music, travel, Iyengar yoga, meditation, and foreign affairs. 

Amy Emerson

Amy Emerson Chief Executive Officer (CEO)

Read Bio
Amy Emerson

Amy Emerson

Chief Executive Officer (CEO)

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. As the Chief Executive Officer, Amy has led the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and implementation of research programs with a focus on the MDMA-assisted psychotherapy program within MAPS PBC.

Amy started as a pro bono consultant at MAPS in 2003, and since then has built MAPS’ clinical department while managing the MDMA Clinical Development Program with a focus on the PTSD indication. In 2014, MAPS Public Benefit Corporation was incorporated to focus on psychedelic drug development, therapist training programs, and future sales of prescription psychedelics prioritizing public benefit above profit.

Amy brings decades of pharmaceutical development and research experience in Phase 1 through Phase 3 Randomized Controlled Trials including supporting three successful regulatory approvals for new biologics. Her professional experience at Novartis, Chiron, and other pharmaceutical companies (1993-2009) spans various fields including immunology, oncology, and vaccines. Pursuing her love of science and nature cultivated while growing up in the woods of Alaska she earned her B.S. in genetics and cell biology from Washington State University in 1992 to prepare for a career in research. Amy is passionate about being a mother and the work of bringing the potential of psychedelics for healing further into the consciousness of the world, leaving a better world for the following generations. She has a lifelong love of travel, living abroad with her husband, exploring in nature, and cooking with her family.

 

 

 

Gisselle Acevedo, M.Ed., J.D., L.M.F.T

Gisselle Acevedo, M.Ed., J.D., L.M.F.T

Gisselle Acevedo is a trauma-informed Marriage and Family therapist and works with people in traditionally marginalized communities. She has served as CEO and in other executive positions across both philanthropic and for-profit organizations, including AT&T, The Los Angeles Times, Para Los Niños, and Ackerman Institute for the Family.

Gisselle has served on the boards of the Harvard John F. Kennedy School of Government, the Los Angeles Area Chamber of Commerce, the Loyola Law School Social Justice Clinic, Health Net, and Farmers Insurance. She is a Regent Emeritus at Loyola Marymount University, Los Angeles, and the Child and Family Guidance Center in Bridgeport, Connecticut.

Gisselle is a graduate of California Institute of Integral Studies Center for Psychedelic Research Therapies and Research. She holds a master’s degree in Marriage and Family Therapy from Fairfield University and a J.D. from Loyola Law School.

Jason Pyle

Jason Pyle

Jason Pyle, M.D., Ph.D., joined Evolve as Managing Director in 2022 to focus his work on the mass mental health crisis and the rampant diseases of despair, which afflict tens of millions of Americans. He is an accomplished biotechnology executive with over twenty years of executive management and technology development experience. He has founded and led successful biotechnology and pharmaceutical firms, including Verdant Pharmaceuticals, Triton Biopharma, Fabric Inc., Sapphire Energy, and Epoc Bioengineering. He is committed to developing healthcare technologies and bringing science-backed healing to the most important problems of our generation. He has received numerous awards for his contributions in biotechnology and his business leadership in the life sciences, including Top 100 Green Executive by Forbes, Top Tech Executive by San Diego Magazine, and National Innovator by the U.S. Department of Energy. He holds several pending and issued patents in the engineering and biological sciences and has worked in diverse cross-discipline areas such as nanofabrication, optical engineering, and structural biology. Jason is a veteran of the U.S. Army and earned an Engineering degree from the University of Arizona. He received both his M.D. and Ph.D. in Molecular and Cellular Physiology from the Stanford University School of Medicine.

Miriam Volat

Miriam Volat

Miriam Volat is the Co-Director of the Riverstyx Foundation and Director of Indigenous Medicine Conservation Fund.

She works personally and professionally to promote health in all systems. Miriam works as a facilitator, educator, and community organizer to increase broad-based community and ecological resilience and decolonize philanthropy. Her work focuses on the intersection of biological and socio-cultural diversity. She has never stopped exploring nutrient cycles and soil ecology, the emphasis of her M.S. work in the U.C. Davis Vegetable Crops Dept. She also has degrees in political science and environmental studies.

Her life’s work at Riverstyx includes supporting efforts that allow issues stigmatized by society to be worked with in a way that brings healing. This includes supporting composting toilets and human bodies and Indigenous medicine, land, and cultural conservation. Riverstyx is committed to supporting a healthful integration of powerful medicines into society in a way that does no harm. As a mom, she is fortunate her daughter, Cora, also supports her work and participates passionately on her many adventures.

Rick Doblin, Ph.D.

Rick Doblin, Ph.D.

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife, dog, and empty rooms from three children, one of whom is in college and two have graduated.

Dawn McCollough

Dawn McCollough

Board Chair

Dawn McCollough has overseen clinical trial support functions and clinical trials involving thousands of patients across numerous indications, geographies, and stages of development for nearly 30 years. Dawn has also helped numerous organizations grow from the ground-up and to operationalize key milestone events in both clinical drug development and business.

Dawn started a consulting company in 2018. In addition to her role at MAPS PBC, she provides consultation to a variety of pharmaceutical, biotech, and CRO clients.

Previously, she headed clinical operations functions in start-up Biotech organizations and headed Medical Research Operations (including the Medical Research Team) in Late-Stage Development at Biogen. Prior to that, Dawn was head of the Global Monitoring Organization for North America at Novartis Vaccines and Diagnostics, based in Cambridge, MA. Dawn began her career with Novartis as Global Head of Clinical Trial Governance in Siena, Italy. Throughout the course of her career, she has participated in the development of numerous drug products from concept to approval. In addition to her time spent in the U.S., she has worked extensively in Europe, Canada, Latin America, and Asia. Dawn has been chosen as a top Women’s Leader within previously affiliated organizations.

Dawn has an entrepreneurial spirit and is passionate about developing new options for patients and for people. She enjoys travel and has a very strong connection with animals, nature, and anything outdoors. She toes the line at ultra-marathons about which she knows “the only way out is through” but revels in the journey and enjoys spending time with friends and family.

Senior Leadership Team

Amy Emerson

Amy Emerson Chief Executive Officer (CEO)

Read Bio
Amy Emerson

Amy Emerson

Chief Executive Officer (CEO)

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. As the Chief Executive Officer, Amy has led the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and implementation of research programs with a focus on the MDMA-assisted psychotherapy program within MAPS PBC.

Amy started as a pro bono consultant at MAPS in 2003, and since then has built MAPS’ clinical department while managing the MDMA Clinical Development Program with a focus on the PTSD indication. In 2014, MAPS Public Benefit Corporation was incorporated to focus on psychedelic drug development, therapist training programs, and future sales of prescription psychedelics prioritizing public benefit above profit.

Amy brings decades of pharmaceutical development and research experience in Phase 1 through Phase 3 Randomized Controlled Trials including supporting three successful regulatory approvals for new biologics. Her professional experience at Novartis, Chiron, and other pharmaceutical companies (1993-2009) spans various fields including immunology, oncology, and vaccines. Pursuing her love of science and nature cultivated while growing up in the woods of Alaska she earned her B.S. in genetics and cell biology from Washington State University in 1992 to prepare for a career in research. Amy is passionate about being a mother and the work of bringing the potential of psychedelics for healing further into the consciousness of the world, leaving a better world for the following generations. She has a lifelong love of travel, living abroad with her husband, exploring in nature, and cooking with her family.

 

 

 

Berra Yazar-Klosinski, Ph.D.

Berra Yazar-Klosinski, Ph.D. Chief Scientific Officer

Read Bio
Berra Yazar-Klosinski, Ph.D.

Berra Yazar-Klosinski, Ph.D.

Chief Scientific Officer

Berra Yazar-Klosinski, Ph.D., is Chief Scientific Officer of the MAPS Public Benefit Corporation (MAPS PBC). Dr. Yazar-Klosinski is responsible for development of strategic, catalytic, and capacity-building activities to facilitate research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. She has been actively involved in the various stages of nonclinical and clinical development of MDMA-assisted psychotherapy, LSD-assisted psychotherapy, cannabis, and ibogaine.

After gaining experience in clinical research laboratories with Geron Corporation and Millennium Pharmaceuticals, Dr. Yazar-Klosinski joined MAPS in 2009 to work with an organization where profit wouldn't dictate the agenda of scientific research. Since 2009, she has supported MAPS clinical research, she has supported MAPS clinical research and regulatory affairs through all stages of growth. Dr. Yazar-Klosinski has developed a strong track record of success with FDA, state regulatory agencies and multiple regulatory agencies outside of the USA.

Dr. Yazar-Klosinski earned her B.S. in Biology with a minor in Drama from Stanford University and her Ph.D. in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz in 2010. She is a Turkish hunter-gatherer who is supporting the growth of her family and pets in harmony with the natural world as she works tirelessly to transform the future.

Andrew “Mo” Septimus

Andrew “Mo” Septimus Chief Financial Officer (CFO) & Co-Head of Business

Read Bio
Andrew “Mo” Septimus

Andrew “Mo” Septimus

Chief Financial Officer (CFO) & Co-Head of Business

Andrew "Mo" Septimus is an experienced entrepreneur with a track record of managing multimillion-dollar raises and budgets, complex projects, and teams. He has worked in private equity and acted as CFO in various industries. Mo brings a compassionate, outgoing, and resourceful leadership style, coupled with practical optimism and a sense of humor. He enjoys craft beverages, hockey, herring, kiddish club, and long walks on the beach. Mo is from Queens, New York, and lives with his family in Surfside, Florida.

Corine de Boer, M.D., Ph.D.

Corine de Boer, M.D., Ph.D. Chief Medical Officer

Read Bio
Corine de Boer, M.D., Ph.D.

Corine de Boer, M.D., Ph.D.

Chief Medical Officer

Corine de Boer, M.D., Ph.D. is the Chief Medical Officer at MAPS Public Benefit Corporation.

She received her medical degree from Radboud University in Nijmegen, the Netherlands and completed residency and fellowship training in pediatrics and pediatric nephrology. Her Ph.D. was focused on peritoneal dialysis in children, and she joined the academic staff at the Radboud University after completing her training.

Before moving to the United States in 2000, she worked as a Pediatrician in the largest inner-city hospital (OLVG) in Amsterdam where she was responsible for in- and outpatient care in a multi-racial patient group including sickle-cell disease, thalassemia, and AIDS.

For the last 20 years, she has contributed to the development of meningococcal and hepatitis vaccines during her tenure at GSK vaccines (formerly Novartis Vaccines and Chiron Corporation) and Dynavax prior to starting her own consulting company where she provides strategic advice and support for a variety of clients working on biologics, small molecule/polymer therapeutics and vaccines.

She feels very fortunate to formally join the MAPS team after assisting them previously in the development of the Pediatric Plans for MDMA. The opportunity that psychedelics provide in the treatment of PTSD and other indications is an exciting scientific field where she feels honored to play a small part in.

Corine resides in beautiful Port Townsend, WA, with her husband and her Jack Russell Terrier where she can be found roaming the beaches, making (wearable) recycled art, and messing around in rowing shells and other boats.

Michael Mullette

Michael Mullette Chief Operating Officer

Read Bio
Michael Mullette

Michael Mullette

Chief Operating Officer

Michael Mullette is an experienced drug development and commercialization expert, currently serving as Chief Operating Officer at MAPS Public Benefit Corporation (MAPS PBC). Mullette most recently served as the Vice President and Managing Director of North America for Moderna, where he oversaw commercialization of the company’s COVID-19 vaccine during the height of the pandemic. 

Jane Mathews

Jane Mathews Chief Compliance Officer

Read Bio
Jane Mathews

Jane Mathews

Chief Compliance Officer

Jane Mathews is MAPS PBC's first Chief Compliance Officer. Jane is responsible for the creation, implementation, and management of MAPS’ compliance program including providing legal advice to the organization with respect to FDA, anti-kickback, state and federal price reporting, Sunshine Act and related state reporting requirements, data privacy and GDPR matters. Jane is a member of the Executive Committee and Co-Chairing the Quality & Compliance Committee.

Jane is an attorney with extensive experience in the pharmaceutical industry. She was formerly Vice President and Chief Compliance Officer for Lexicon Pharmaceuticals, Assistant General Counsel for Sunovion Pharmaceuticals, and Head of Litigation for Hoffmann La Roche.

Jane resides in New Jersey.

Arman Nadershahi

Arman Nadershahi General Counsel

Read Bio
Arman Nadershahi

Arman Nadershahi

General Counsel

Arman is a seasoned legal executive who has served various life science companies ranging from early-stage startups to multinational biopharma companies. He has extensive experience working with not-for-profit organizations and their public benefit corporate subsidiaries.

Arman’s experience spans corporate law, FDA law, securities law, employment law, intellectual property law, M&A law, and healthcare risk management and compliance. Arman has established and led numerous legal and cross-functional teams. He has played a key role in, business financing strategies, product research and development, FDA approvals, market access, commercialization, numerous acquisitions and divestitures, and initial public offerings.

Previously, Arman served as Associate General Counsel at Gyroscope Therapeutics, a gene therapy and medical device company acquired by Novartis. Prior to Gyroscope, Arman served as the Head of Legal at the Alfred Mann Institute for Biomedical Engineering at the University of Southern California (AMI-USC). At AMI-USC, he led the legal function of a $200M life science incubator, as well as the formation, financing, and successful exits of numerous medical device startup companies. Earlier in his career, Arman practiced intellectual property law at Knobbe, Martens, Olson & Bear, LLP, where he focused on patent prosecution, licensing, and intellectual property litigation in the fields of biotechnology, pharmaceuticals, and medical devices.

Additionally, Arman co-founded and served as General Counsel and Chairman of Global Brigades, Inc., a 501(c)(3) organization focused on global health and holistic community development. He also teaches biotechnology law at University of Southern California in his spare time.

Arman graduated with distinction from the University of Wisconsin-Madison with a BA in Zoology and English. He earned a Juris Doctor from the University of Minnesota Law School, a Master’s in Biological Science from the University of Minnesota, an MS in Regulatory Science from the University of Southern California School of Pharmacy, an MBA from the Marshall School of Business at the University of Southern California, and an LLM in Securities and Financial Regulation from Georgetown Law Center. He is a registered patent attorney, holds US and EU regulatory affairs certifications, and is a Fellow of the American Institute for Medical and Biological Engineering.

Arman enjoys reading, playing tennis, cooking, and spending time with his wife, their two sons, and their cat.

MAPS Public Benefit Corporation

Our Mission
Who We Are
Careers
News
FAQ
Contact Us

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

Therapy Training

Overview
Application

MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about MDMA Therapy Training

You have Successfully Subscribed!